Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)

Powles, Thomas; Motzer, Robert J.; George, Daniel J.; Jonasch, Eric; Pal, Sumanta K.; Tannir, Nizar M.; Signoretti, Sabina; Mai, Tu; Scheffold, Christian; Wang, E.; Aftab, Dana T.; Escudier, Bernard; Choueiri, Toni K.

doi:10.1093/annonc/mdx371.026

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…97,112–115 The remaining studies included various biomarkers, such as plasma and cell biomarkers. 34,47,53,78,81,82,91,94,96,103,116–127…”

Section: Resultsmentioning

confidence: 99%

“…Of 114 articles identified from the SLR, 54 report findings related to biomarkers. The biomarkers identified include RET mutational status (seven studies), 12,[64][65][66][67]101,104 presence of bone metastases (five studies), 28,40,66,105,106 MET expression level (five studies), 18,19,29,107,108 RAS mutational status (four studies), 67,92,101,104 circulating tumor cells (two studies), 73,102 and alpha-fetoprotein (three studies). [109][110][111] Six studies investigated tumor characteristics, including diameter and volume.…”

Section: Therapeutic Advances Inmentioning

confidence: 99%

“…97,[112][113][114][115] The remaining studies included various biomarkers, such as plasma and cell biomarkers. 34,47,53,78,81,82,91,94,96,103,[116][117][118][119][120][121][122][123][124][125][126][127] RET status was the most commonly investigated biomarker; all seven studies were subgroup analyses of MTC study populations. Patients with positive RET-mutation status (mainly RET M918T) generally experienced greater cabozantinib treatment benefit (prolonged OS and PFS with cabozantinib versus placebo) than patients without RET mutations.…”

Section: Therapeutic Advances Inmentioning

confidence: 99%

See 2 more Smart Citations

Cabozantinib for the treatment of solid tumors: a systematic review

et al. 2022

View full text Add to dashboard Cite

Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. With the available evidence and the real-world performance of cabozantinib compared with clinical trial data, we performed a systematic review of cabozantinib monotherapy as treatment for solid tumors in adults. Methods: This study was designed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses and registered with PROSPERO (CRD42020144680). We searched for clinical and observational studies of cabozantinib monotherapy for solid tumors using Embase, MEDLINE, and Cochrane databases (October 2020), and screened relevant congress abstracts. Eligible studies reported clinical or safety outcomes, or biomarker data. Small studies ( n < 25) and studies of cabozantinib combination therapies were excluded. Quality was assessed using National Institute for Health and Care Excellence methodology, and study characteristics were described qualitatively. Results: Of 2888 citations, 114 were included (52 randomized studies, 29 observational studies, 32 nonrandomized phase I or II studies or pilot trials, and 1 analysis of data from a randomized study and a nonrandomized study). Beyond approved indications, other tumors studied were castration-resistant prostate cancer, urothelial carcinoma, Ewing sarcoma, osteosarcoma, uveal melanoma, non-small-cell lung cancer, Merkel cell carcinoma, glioblastoma, pheochromocytomas and paragangliomas, cholangiocarcinoma, gastrointestinal stromal tumor, colorectal cancer, salivary gland cancer, carcinoid and pancreatic neuroendocrine tumors, and breast, endometrial and ovarian cancers. The most common adverse events were hypertension, diarrhea, and fatigue. Conclusion: The identified evidence demonstrates the positive efficacy/effectiveness of cabozantinib monotherapy in various solid tumor types, with safety findings being consistent with those observed with other VEGFR-targeting tyrosine kinase inhibitors. When available, real-world findings were consistent with the data reported from clinical trials. A limitation of this review is the high proportion of abstracts; however, this allowed us to capture the most up-to-date findings.

show abstract